Thrombotic thrombocytopenic purpura

Editor-In-Chief: Prab R Tumpati, MD
Obesity, Sleep & Internal medicine
Founder, WikiMD Wellnesspedia &
W8MD medical weight loss NYC and sleep center NYC

Thrombotic thrombocytopenic purpura
Synonyms	TTP
Pronounce	N/A
Specialty	N/A
Symptoms	Purpura, petechiae, anemia, neurological symptoms, renal failure
Complications	Stroke, myocardial infarction, renal failure
Onset	Sudden
Duration	Variable
Types	N/A
Causes	ADAMTS13 deficiency, autoimmune disease, genetic mutation
Risks	HIV, pregnancy, cancer, chemotherapy
Diagnosis	Blood test, ADAMTS13 activity, clinical presentation
Differential diagnosis	Hemolytic uremic syndrome, immune thrombocytopenic purpura, disseminated intravascular coagulation
Prevention	N/A
Treatment	Plasma exchange, corticosteroids, rituximab
Medication	N/A
Prognosis	Variable, can be life-threatening
Frequency	3-4 cases per million per year
Deaths	10-20% with treatment

Thrombotic thrombocytopenic purpura (TTP) is a rare and potentially life-threatening blood disorder characterized by the formation of small blood clots (thrombi) throughout the body. These blood clots can cause damage to organs and tissues and lead to a low platelet count (thrombocytopenia), which results in easy bruising and bleeding.

Thrombotic Thrombocytopenic Purpura (TTP)

Causes and Pathophysiology

• TTP is primarily caused by a deficiency or dysfunction of a specific enzyme called ADAMTS13 (a disintegrin and metalloproteinase with thrombospondin type 1 motif, member 13). ADAMTS13 is responsible for breaking down von Willebrand factor (vWF), a protein that helps with blood clotting. When ADAMTS13 is deficient or not functioning properly, there is an accumulation of large vWF multimers in the blood, leading to abnormal clot formation.
• In most cases, TTP is acquired, meaning it develops during a person's lifetime and is not inherited. Acquired TTP can be associated with the presence of autoantibodies that target and inhibit ADAMTS13 activity. These autoantibodies can be triggered by various factors, including infections, certain medications, autoimmune diseases, pregnancy, and cancer.

Signs and Symptoms

• The classic pentad of TTP includes the following five features, although not all may be present in every case:
• Microangiopathic Hemolytic Anemia: This refers to the destruction of red blood cells as they pass through small blood vessels obstructed by blood clots. It can result in fatigue, weakness, pale skin, and jaundice.
• Thrombocytopenia: TTP leads to a low platelet count, which can cause easy bruising, petechiae (small red or purple spots on the skin), and excessive bleeding.
• Fever: Some individuals with TTP may experience fever, although it is not always present.
• Neurologic Symptoms: TTP can affect the central nervous system and lead to symptoms such as confusion, headache, seizures, visual changes, and even coma.
• Renal Dysfunction: Kidney involvement can occur in TTP, resulting in decreased urine output, kidney failure, and signs of kidney damage.

Diagnosis and Treatment

• The diagnosis of TTP is based on a combination of clinical features, blood tests, and specialized laboratory evaluations. Laboratory findings may include evidence of microangiopathic hemolytic anemia, thrombocytopenia, and an elevated lactate dehydrogenase (LDH) level. ADAMTS13 activity testing and the presence of ADAMTS13 autoantibodies can help confirm the diagnosis.
• Immediate treatment is crucial in TTP to prevent complications and reduce mortality. The standard treatment approach involves plasma exchange (also known as plasmapheresis), which involves removing a patient's plasma and replacing it with fresh frozen plasma or a plasma substitute. Plasma exchange helps remove the autoantibodies and replenish ADAMTS13 activity. High-dose corticosteroids and immunosuppressive medications may also be administered to inhibit the formation of autoantibodies.
• In severe cases or when plasma exchange is not readily available, other treatments such as rituximab (a monoclonal antibody) or caplacizumab (a medication that blocks vWF) may be considered. Supportive care, including blood transfusions, close monitoring, and management of complications, is an important part of TTP treatment.

Prognosis

With prompt diagnosis and appropriate treatment, the prognosis for TTP has improved significantly. However, TTP is still a serious condition that requires close medical management. Early intervention and ongoing monitoring are crucial to prevent relapses and manage potential long-term complications.

Summary

Thrombotic thrombocytopenic purpura (TTP) is a rare blood disorder characterized by the formation of blood clots throughout the body, leading to low platelet count and organ damage. It is primarily caused by a deficiency or dysfunction of the ADAMTS13 enzyme, which affects the breakdown of vWF. Prompt diagnosis and treatment, including plasma exchange and immunosuppressive medications, are essential in managing TTP and improving outcomes.

See Also

• Hemolytic Anemia
• Thrombosis
• Autoimmune Diseases
• Plasma Exchange Therapy

References

This article is a medical stub. You can help WikiMD by expanding it!
Most recent articles Ongoing trials	Wikipedia